ArticleEuropean radiology2026
Toward perioperative, numerically assisted irreversible electroporation for hepatocellular carcinoma: clinical outcomes informed by numerical simulations.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and Efficacy of an Irreversible Electroporation System with Real-Time Electrical and Thermal Monitoring for Liver Tumors: A Bicentric Retrospective Study.Cardiovascular and interventional radiology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesNumerical evaluation of irreversible electroporation (IRE) holds significant potential to assist practitioners in planning and guiding these complex procedures. We aimed to establish a correlation between the results of retrospective numerical simulations of IRE and clinical outcomes in the treatment of hepatocellular carcinoma (HCC). MATERIALS AND
methodsIRE procedures conducted at our center for HCCs < 5 cm were reconstructed. Per-procedural imaging was used to generate a 3D geometric model of the tumor and its surroundings. The spatial coordinates of electrodes and treatment parameters were used to retrospectively simulate the EF using the static linear model. The proportion of tumor volume encompassed by 3D mappings of different EF magnitudes was correlated with clinical efficacy using a logistic regression algorithm.
results31 IRE procedures were included. HCCs had a median diameter of 20 mm (range: 7-45 mm). At 1 month, 29/31 tumors (93.5%) showed complete ablation, but 10 of these recurred later (median delay: 7 months). The percentages of tumor coverage by EF isolines were significantly lower in the 12 cases of local IRE failure compared to the 19 cases of IRE success: 97.7% vs. 100% at 300 V/cm (p < 0.001); 89.7% vs. 100% at 400 V/cm (p < 0.001) and 82.8% vs. 95.4% at 500 V/cm (p < 0.01) with 400 V/cm being the most discriminative threshold dose (ROC-AUC: 0.904). Tumor coverage < 95% by the 400 V/cm isoline was associated with IRE failure (2-year incidence: 89% vs. 21.7%, p < 0.0001).
conclusionNumerical simulations of IRE correlate with local treatment outcomes. This study suggests that, in HCC, inadequate tumor coverage by the 400 V/cm isoline predicts and localizes recurrence. KEY POINTS: Question Can the clinical outcomes of irreversible electroporation for hepatocellular carcinoma be predicted using numerical simulation of the electric field (EF) distribution? Findings Inadequate tumor coverage by simulated EF maps predicts and localizes recurrence, with 400 V/cm being the most discriminative isodose threshold (ROC-AUC > 0.9). Clinical relevance Numerical simulations of the electric field correlate with local treatment outcomes of irreversible electroporation for hepatocellular carcinoma within a computational framework compatible with clinical use. Real-time identification of insufficient tumor coverage can enable operators to adapt and optimize treatment delivery.
Indexed as
Identifiers
41417128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.